These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 20110075)

  • 1. [Paradoxical cutaneous manifestations during anti-TNF-alpha therapy].
    Viguier M; Richette P; Bachelez H; Wendling D; Aubin F
    Ann Dermatol Venereol; 2010 Jan; 137(1):64-71; quiz 63, 78-9. PubMed ID: 20110075
    [No Abstract]   [Full Text] [Related]  

  • 2. Cutaneous manifestations in inflammatory bowel diseases: eight cases of psoriasis induced by anti-tumor-necrosis-factor antibody therapy.
    Passarini B; Infusino SD; Barbieri E; Varotti E; Gionchetti P; Rizzello F; Morselli C; Tambasco R; Campieri M
    Dermatology; 2007; 215(4):295-300. PubMed ID: 17911986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Granulomatous Drug Eruptions.
    Dodiuk-Gad RP; Shear NH
    Dermatol Clin; 2015 Jul; 33(3):525-39. PubMed ID: 26143430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of cutaneous sarcoidosis during treatment with tumour necrosis alpha factor antagonists.
    Lamrock E; Brown P
    Australas J Dermatol; 2012 Nov; 53(4):e87-90. PubMed ID: 23157794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Psoriasiform eruptions during anti TNF-alpha treatment: psoriasis or not?
    Seneschal J; Lepreux S; Milpied B; Schaeverbeke T; Taïeb A
    Arch Dermatol; 2007 Dec; 143(12):1593-5; author reply 1595. PubMed ID: 18087021
    [No Abstract]   [Full Text] [Related]  

  • 6. Tumour necrosis factor inhibition causing psoriasis? A more plausible explanation exists.
    Carter JD
    Ann Rheum Dis; 2006 Dec; 65(12):1680. PubMed ID: 17105866
    [No Abstract]   [Full Text] [Related]  

  • 7. Leucocytoclastic vasculitis associated with golimumab.
    Pàmies A; Castro S; Poveda MJ; Fontova R
    Rheumatology (Oxford); 2013 Oct; 52(10):1921-3. PubMed ID: 23530254
    [No Abstract]   [Full Text] [Related]  

  • 8. Psoriasis and pustular dermatitis triggered by TNF-{alpha} inhibitors in patients with rheumatologic conditions.
    de Gannes GC; Ghoreishi M; Pope J; Russell A; Bell D; Adams S; Shojania K; Martinka M; Dutz JP
    Arch Dermatol; 2007 Feb; 143(2):223-31. PubMed ID: 17310002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In SAPHO syndrome anti-TNF-alpha therapy may induce persistent amelioration of osteoarticular complaints, but may exacerbate cutaneous manifestations.
    Massara A; Cavazzini PL; Trotta F
    Rheumatology (Oxford); 2006 Jun; 45(6):730-3. PubMed ID: 16403830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dermatological complications and safety of anti-TNF treatments.
    Kerbleski JF; Gottlieb AB
    Gut; 2009 Aug; 58(8):1033-9. PubMed ID: 19592682
    [No Abstract]   [Full Text] [Related]  

  • 11. Psoriasis after treatment of juvenile idiopathic arthritis with etanercept.
    Peek R; Scott-Jupp R; Strike H; Clinch J; Ramanan AV
    Ann Rheum Dis; 2006 Sep; 65(9):1259. PubMed ID: 16905590
    [No Abstract]   [Full Text] [Related]  

  • 12. Leukocytoclastic vasculitis associated with tumor necrosis factor-alpha blocking agents.
    Mohan N; Edwards ET; Cupps TR; Slifman N; Lee JH; Siegel JN; Braun MM
    J Rheumatol; 2004 Oct; 31(10):1955-8. PubMed ID: 15468359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pityriasis amiantacea: a distinctive presentation of psoriasis associated with tumour necrosis factor-α inhibitor therapy.
    Ettler J; Wetter DA; Pittelkow MR
    Clin Exp Dermatol; 2012 Aug; 37(6):639-41. PubMed ID: 22300412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review article: anti TNF-alpha induced psoriasis in patients with inflammatory bowel disease.
    Fiorino G; Allez M; Malesci A; Danese S
    Aliment Pharmacol Ther; 2009 May; 29(9):921-7. PubMed ID: 19210297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A medical conundrum: onset of psoriasis in patients receiving anti-tumour necrosis factor agents.
    Ritchlin C; Tausk F
    Ann Rheum Dis; 2006 Dec; 65(12):1541-4. PubMed ID: 17105851
    [No Abstract]   [Full Text] [Related]  

  • 16. Development of rheumatoid nodules during anti-tumor necrosis factor alpha therapy with etanercept.
    Kekow J; Welte T; Kellner U; Pap T
    Arthritis Rheum; 2002 Mar; 46(3):843-4. PubMed ID: 11920425
    [No Abstract]   [Full Text] [Related]  

  • 17. Granulomatous Cutaneous Drug Eruptions: A Systematic Review.
    Shah N; Shah M; Drucker AM; Shear NH; Ziv M; Dodiuk-Gad RP
    Am J Clin Dermatol; 2021 Jan; 22(1):39-53. PubMed ID: 33108647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Psoriasiform and pustular eruption induced by infliximab.
    Takahashi H; Hashimoto Y; Ishida-Yamamoto A; Ashida T; Kohgo Y; Iizuka H
    J Dermatol; 2007 Jul; 34(7):468-72. PubMed ID: 17584325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optic neuritis associated with tumor necrosis factor-alfa antagonists for the treatment of psoriasis.
    de Masson A; Ben Said B; Parier J; Begon E; Augey F; Goujon C; Dahel K; Nicolas JF; Bérard F; Bachelez H; Bagot M; Bouaziz JD
    J Am Acad Dermatol; 2012 Dec; 67(6):e280-2. PubMed ID: 23158640
    [No Abstract]   [Full Text] [Related]  

  • 20. Facial granulomatous nodules during etanercept treatment for psoriasis.
    Samimi M; Lorette G; Machet L; de Muret A; Watier H; Maruani A
    Int J Dermatol; 2009 Sep; 48(9):1025-7. PubMed ID: 19703000
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.